International Journal of
Reproductive Biomedicine
Sat, Apr 27, 2024
[Archive]
Volume 11, Issue 4 (6-2013)
IJRM 2013, 11(4): 261-0 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Yassin M M, Sharif F A, Laqqan M M. Anti-mullerian hormone as a predictor of ovarian reserve and ovarian response in IVF women from Gaza strip. IJRM 2013; 11 (4) :261-0
URL: http://ijrm.ir/article-1-411-en.html
URL: http://ijrm.ir/article-1-411-en.html
1- Department of Physiology, Faculty of Medicine, The Islamic University of Gaza, Gaza Strip, Palestine
2- Department of Molecular Biology, Faculty of Sciences, The Islamic University of Gaza, Gaza Strip, Palestine
3- Lecture at Faculty of Medicine, The Islamic University of Gaza, Gaza Strip, Palestine , mlaqqan@iugaza.edu.ps
2- Department of Molecular Biology, Faculty of Sciences, The Islamic University of Gaza, Gaza Strip, Palestine
3- Lecture at Faculty of Medicine, The Islamic University of Gaza, Gaza Strip, Palestine , mlaqqan@iugaza.edu.ps
Abstract: (3477 Views)
Background: Careful evaluation of patients and proper treatment with right techniques are essential for successful outcome of assisted reproduction. To obtain satisfactory results, it is necessary to assess ovarian reserve before planning treatment.
Objective: To evaluate anti-mullerian hormone as a predictor of fertility potential in terms of ovarian reserve and ovarian response reflected by antral follicles and mature oocyte counts in response to menotrophin stimulation in in vitro fertilization (IVF) women from Gaza Strip.
Materials and Methods: This prospective cohort study consisted of 81 women (mean age 28.7 years) attending IVF at Al-Basma Fertility Center in Gaza City. Blood withdrawal for antimullerian hormone measurement was performed in all the patients and the number of oocytes and embryos were recorded.
Results: The total number of retrieved oocytes was inversely associated with age (12.5±4.5, 11.0±5.4 and 6.9±4.7 at age ≤25, 26-35 and >35 years, respectively (F=4.793 and p=0.011). The ovarian response to Menotrophin (FSH 75IU, LH 75 IU) stimulation was better for younger age. There was a significant positive association between ovarian response in terms of total number of oocytes and antimullerian hormone levels. The maximum level of antimullerian hormone was observed in females who achieved positive pregnancies (4.5±2.5 ng/mL) followed by negative pregnancies (2.9±1.8 ng/mL) with significant differences (F=6.862 and p=0.002). Correlation coefficient revealed that the number of mature oocytes showed strong positive correlation with the antimullerian hormone levels (r=0.469, p=0.001).
Conclusion: Anti-mullerian hormone can be used in IVF programs as a good predictor of ovarian reserve and ovarian response.
Objective: To evaluate anti-mullerian hormone as a predictor of fertility potential in terms of ovarian reserve and ovarian response reflected by antral follicles and mature oocyte counts in response to menotrophin stimulation in in vitro fertilization (IVF) women from Gaza Strip.
Materials and Methods: This prospective cohort study consisted of 81 women (mean age 28.7 years) attending IVF at Al-Basma Fertility Center in Gaza City. Blood withdrawal for antimullerian hormone measurement was performed in all the patients and the number of oocytes and embryos were recorded.
Results: The total number of retrieved oocytes was inversely associated with age (12.5±4.5, 11.0±5.4 and 6.9±4.7 at age ≤25, 26-35 and >35 years, respectively (F=4.793 and p=0.011). The ovarian response to Menotrophin (FSH 75IU, LH 75 IU) stimulation was better for younger age. There was a significant positive association between ovarian response in terms of total number of oocytes and antimullerian hormone levels. The maximum level of antimullerian hormone was observed in females who achieved positive pregnancies (4.5±2.5 ng/mL) followed by negative pregnancies (2.9±1.8 ng/mL) with significant differences (F=6.862 and p=0.002). Correlation coefficient revealed that the number of mature oocytes showed strong positive correlation with the antimullerian hormone levels (r=0.469, p=0.001).
Conclusion: Anti-mullerian hormone can be used in IVF programs as a good predictor of ovarian reserve and ovarian response.
Type of Study: Original Article |
References
1. Cate L, Mattaliano J, Hession C, Tizard R, Farber M, Cheung A, et al. Isolation of the bovine and human genes for Mullerian inhibiting substance and expression of the human gene in animal cells. Cell 1986; 45: 685-698. [DOI:10.1016/0092-8674(86)90783-X]
2. Maheswaran S, Teixeira J, Donahoe K. Mullerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications. Endocrine Rev 2001; 22: 657-674.
3. La Marca A, Giulini S, Tirelli A, Bertucci E, Marsella T, Xella S, et al. Anti-Mullerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Reprod 2006; 22: 766-771. [DOI:10.1093/humrep/del421]
4. Durlinger L, Kramer P, Karels P, Hoogerbrugges W, van Leeuwen C. Endocrinology 1999; 140: 5789-5796.
5. Laqqan M .Antimullerian hormone as a predictor of ovarian reserve and ovarian response in IVF candidates. Master thesis, The Islamic University of Gaza; 2010.
6. Weenen C, Laven S, Von Bergh R, Cranfield M, Groome P, Visser A, et al. Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 2004; 10: 77-83. [DOI:10.1093/molehr/gah015]
7. Jorgensen N, Rajpert-De Meyts E, Graem N, Muller J, Cate R, Skakkebaek N. Expression of anti-Mullerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. Clin Endocrinol Metabol 1999; 84: 3836-3844.
8. Lee M, Donahoe K. Mullerian inhibiting substance: a gonadal hormone with multiple functions. Endocrine Rev 1993; 14: 152-164.
9. Munsterberg A, Lovell-Badge R. Expression of the mouse anti-Mullerian hormone gene suggests a role in both male and female sexual differentiation. Development 1991; 113: 613-624.
10. Durlinger A, Visser J, Themmen A. Regulation of ovarian function: the role of anti-Mullerian hormone. Reproduction 2002; 124: 601-609. [DOI:10.1530/rep.0.1240601]
11. Wunder M, Bersinger A, Yared M, Kretschmer R, Birkhauser H. Statistically significant changes of anti m mullerian hormone and inhibin levels during the physiologic menstrual cycle in reproductive age women. Fertil Steril 2008; 89: 927-933. [DOI:10.1016/j.fertnstert.2007.04.054]
12. Firouzabadi R, Tayebi N, Asgharnia M. Serum Level of Anti-Mullerian Hormone in Early Follicular Phase as a Predictor of Ovarian Reserve and Pregnancy Outcome in Assisted Reproductive Technology Cycles. Arch Iran Med 2008; 11: 371-376.
13. Freiesleben L, Rosendahl M, Johannsen T, Lossl K, Loft A, Bangsboll S, et al. Prospective investigation of serum anti-Mullerian hormone concentration in ovulatory intrauterine insemination patients: a preliminary study Reproductive. Biomed 2010; 20: 582-587. [DOI:10.1016/j.rbmo.2010.02.007]
14. Shahin A. The problem of IVF cost in developing countries: has natural cycle IVF a place? Reprod Biomed Online 2007; 15: 51-56.
15. Dehghani-Firouzabadi R, Tayebi N, Asgharnia M. Serum Level of Anti-mullerian Hormone in Early Follicular Phase as a Predictor of Ovarian Reserve and Pregnancy Outcome in Assisted Reproductive Technology Cycles. Arch Iran Med 2008; 11: 4.
16. Van Rooij A, Broekmans J, Te Velde R, Fauser C, Bancsi F, De Jong H, et al. Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod 2002; 17: 3065-3071. [DOI:10.1093/humrep/17.12.3065]
17. Ficicioglu C, Kutlu T, Baglam E, Bakacak Z. Early follicular anti-müllerian hormone as an indicator of ovarian reserve. Fertil Steril 2006; 85: 592-596. [DOI:10.1016/j.fertnstert.2005.09.019]
18. La Marca A, Spada E, Grisendi V, Argento C, Papaleo E, Milani S, et al. Normal serum anti-Müllerian hormone levels in the general female population and the relationship with reproductive history. Obstet Gynecol Reprod Biol 2012; 163: 180-184. [DOI:10.1016/j.ejogrb.2012.04.013]
19. Abbas A, Homa O, Shahnaz A, Leila O. Prediction of high ovarian response to controlled ovarian hyperstimulation: anti-Müllerian hormone versus small antral follicle count (2-6 mm). Assist Reprod Genet 2009; 26: 319-325. [DOI:10.1007/s10815-009-9319-5]
20. Usta T, Oral E. Is the measurement of anti-Müllerian hormone essential? Current Opin Obstet Gynecol 2012; 24: 151-157.
21. Tolikas A, Tsakos E, Gerou S, Prapas Y, Loufopoulos A. Anti-Mullerian Hormone (AMH) levels in serum and follicular fluid as predictors of ovarian response in stimulated (IVF and ICSI) cycles. Hum Fertil (Cambridge) 2011; 14: 246-253. [DOI:10.3109/14647273.2011.608464]
22. Seifer D, MacLaughlin D, Christian B, Feng B, Shelden R. Early follicular serum Mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 2002; 77: 468-471. [DOI:10.1016/S0015-0282(01)03201-0]
23. Fanchin R, Schonauer L, Righini C, Guibourdenche J, Frydman R, Taieb J. Serum anti-Mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, FSH, and LH on day 3. Hum Reprod 2003; 18: 323-327. [DOI:10.1093/humrep/deg042]
24. Marzieh H, Ashraf A, Atossa M, Sara M, Leila S, Parvin F. Relationship between anti-mullerian hormone and assisted reproductive technique outcome in patients with polycystic ovary syndrome. Iran J Reprod Med 2010; 8: 161-166.
25. Smeenk J, Sweep F, Zielhuis G, Kremer J, Thomas C, Braat D. Anti-mullerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracyoplasmic sperm injection. Fertil Steril 2007; 87: 223-226. [DOI:10.1016/j.fertnstert.2006.06.019]
26. Fridén B, Sjöblom P, Menezes J. Using anti-Müllerian hormone to identify a good prognosis group in women of advanced reproductive age. Aus NZJ Obstet Gynaecol 2011; 51: 411-415.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
